
Please try another search
Imagion Biosystems Limited provides medical imaging technologies based on superparamagnetic relaxometry for cancer and disease detection, and monitoring therapy. It has activities in nanotechnology; biotechnology; cancer diagnostics; and superparamagnetic relaxometry. The company develops MagSense, which is in Phase I clinical trials for the treatment of HER2 breast cancers; and PrecisionMRX, an iron oxide nanoparticle to detect cancer. Imagion Biosystems Limited has a collaborative research program with Patrys Limited to use the combined technologies for enhancing brain tumor imaging and diagnosis; and a joint development agreement with Global Cancer Technology, Inc. to develop GCT’s novel nanoscintillator technology for the treatment of breast cancer. The company was incorporated in 2016 and is based in San Diego, California.
Name | Age | Since | Title |
---|---|---|---|
Michael John Harsh | 68 | 2017 | Non-Executive Director |
Robert Ivkov | - | 2019 | Member of Scientific Advisory Board |
David Gerald Ludvigson | 71 | 2017 | Non Executive Director |
Robert Romeo Proulx | 64 | 2015 | Executive Chairman, President & CEO |
John Hazle | - | 2018 | Chairman of Scientific Advisory Board |
Mark Gerland Van Asten | - | 2016 | Non Executive Director |
Andrew M. Scott | - | 2019 | Member of Scientific Advisory Board |
Jovanka Naumoska | - | 2016 | Non Executive Director |
Lisa Horvath | - | 2019 | Member of Scientific Advisory Board |
Paul C. Grint | 64 | 2019 | Member of Scientific Advisory Board |
Dianne M. Angus | 62 | 2020 | Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review